Immunovaccine Clarifies May 12, 2014 Trading Activity

NOT FOR DISSEMINATION IN THE UNITED STATES OR THROUGH U.S. NEWSWIRE SERVICES

Immunovaccine Inc. ("Immunovaccine" or the "Company") (TSX VENTURE:IMV)
announces that the Investment Industry Regulatory Organization of Canada
("IIROC"), the regulation services provider of the TSX Venture Exchange, has
authorized the resumption of trading in Immunovaccine's shares at 3:45 p.m. on
May 12, 2014 at a price of $0.65 per share. This follows the decision by IIROC
to halt trading of Immunovaccine shares at 2:46 p.m. based on perceived
irregularities in trading activity. This decision was made in accordance with
IIROC's Universal Market Integrity Rules (UMIR) which are designed to ensure
fairness and maintain investor confidence.


After looking into the matter, IIROC determined that unintended and unreasonable
trades were made as a result of a key error ("fat finger" error). This error
caused a rapid and unintended decrease in the price of Immunovaccine stock.
Following its investigation, IIROC has ruled that all trades in the common
shares of Immunovaccine that took place prior to 2:41 p.m. on May 12, 2014 at
prices below $0.65 will be cancelled or repriced to $0.65 per share. 


About Immunovaccine

Immunovaccine Inc. develops cancer immunotherapies and infectious disease
vaccines based on the Company's DepoVax(TM) platform, a patented formulation
that provides controlled and prolonged exposure of antigens and adjuvants to the
immune system. Immunovaccine has advanced two T cell activation therapies for
cancer through Phase I human clinical trials. Lead cancer vaccine therapy,
DPX-Survivac, is expected to enter Phase II clinical studies in 2014, in ovarian
cancer and glioblastoma (brain cancer). The Company is also advancing an
infectious disease pipeline including innovative vaccines for respiratory
syncytial virus (RSV) and anthrax. 


Connect at www.imvaccine.com.

This press release contains forward-looking information under applicable
securities law. All information that addresses activities or developments that
we expect to occur in the future, is forward-looking information.
Forward-looking statements are based on the estimates and opinions of management
on the date the statements are made. However, they should not be regarded as a
representation that any of the plans will be achieved. Actual results may differ
materially from those set forth in this press release due to risks affecting the
company, including access to capital, the successful completion of clinical
trials and receipt of all regulatory approvals. Immunovaccine Inc. assumes no
responsibility to update forward-looking statements in this press release except
as required by law. 


Neither TSX Venture Exchange nor its Regulation Services Provider (as that term
is defined in the policies of the TSX Venture Exchange) accepts responsibility
for the adequacy or accuracy of this release.


FOR FURTHER INFORMATION PLEASE CONTACT: 
Immunovaccine Inc.
Kimberly Stephens
Chief Financial Officer
(902) 492-1819
mmansour@imvaccine.com
www.imvaccine.com


Vida Strategic Partners (media)
Tim Brons
(415) 675-7402
tbrons@vidasp.com

(TSXV:IMV)
Graphique Historique de l'Action
De Juin 2024 à Juil 2024